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BACKGROUND: Factor VIII (FVIII) and its carrier protein von Willebrand 
factor (VWF) are associated with risk of arterial and venous thrombosis 
and with hemorrhagic disorders. We aimed to identify and functionally 
test novel genetic associations regulating plasma FVIII and VWF.
METHODS: We meta-analyzed genome-wide association results from 
46 354 individuals of European, African, East Asian, and Hispanic 
ancestry. All studies performed linear regression analysis using an 
additive genetic model and associated ≈35 million imputed variants 
with natural log–transformed phenotype levels. In vitro gene silencing in 
cultured endothelial cells was performed for candidate genes to provide 
additional evidence on association and function. Two-sample Mendelian 
randomization analyses were applied to test the causal role of FVIII and 
VWF plasma levels on the risk of arterial and venous thrombotic events.
RESULTS: We identified 13 novel genome-wide significant (P≤2.5×10−8) 
associations, 7 with FVIII levels (FCHO2/TMEM171/TNPO1, HLA, SOX17/
RP1, LINC00583/NFIB, RAB5C-KAT2A, RPL3/TAB1/SYNGR1, and ARSA) 
and 11 with VWF levels (PDHB/PXK/KCTD6, SLC39A8, FCHO2/TMEM171/
TNPO1, HLA, GIMAP7/GIMAP4, OR13C5/NIPSNAP, DAB2IP, C2CD4B, 
RAB5C-KAT2A, TAB1/SYNGR1, and ARSA), beyond 10 previously reported 
associations with these phenotypes. Functional validation provided further 
evidence of association for all loci on VWF except ARSA and DAB2IP. 
Mendelian randomization suggested causal effects of plasma FVIII activity 
levels on venous thrombosis and coronary artery disease risk and plasma 
VWF levels on ischemic stroke risk.
CONCLUSIONS: The meta-analysis identified 13 novel genetic loci 
regulating FVIII and VWF plasma levels, 10 of which we validated 
functionally. We provide some evidence for a causal role of these proteins 
in thrombotic events.
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Maria Sabater-Lleal, PhD
Jennifer E. Huffman, PhD
Paul S. de Vries, PhD
Jonathan Marten, BSc
et al
ORIGINAL RESEARCH ARTICLE
Genome-Wide Association Transethnic 
Meta-Analyses Identifies Novel Associations 
Regulating Coagulation Factor VIII and von 
Willebrand Factor Plasma Levels
https://www.ahajournals.org/journal/circ
Circulation
September122018
D
ow
nloaded from
 http://ahajournals.org by on March 1, 2019
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
12
73
74
 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
Sabater-Lleal et al Genetic Regulation of FVIII and VWF
Circulation. 2019;139:620–635. DOI: 10.1161/CIRCULATIONAHA.118.034532 January 29, 2019 621
ORIGINAL RESEARCH 
ARTICLE
Factor VIII (FVIII) and its carrier protein von Wil-lebrand factor (VWF) regulate hemostasis and thrombosis, and higher plasma levels of these fac-
tors have been associated with risk of arterial and ve-
nous thrombosis, whereas lower levels are associated 
with hemorrhagic disorders1–4 and with reduced risk 
of thrombotic events.5 Previously published genetic as-
sociation studies have investigated the contribution of 
nucleotide variation to plasma levels of these factors 
using genome-wide and exome-wide markers.6–8 These 
studies identified and replicated 8 genetic loci associ-
ated with plasma VWF levels (STXBP5, SCARA5, ABO, 
STAB2, STX2, VWF, TCN2 and CLEC4M), 5 of which 
were also associated with FVIII levels (STXBP5, SCARA5, 
ABO, STAB2, and VWF). These discoveries have broad-
ened our understanding of the regulation of hemosta-
sis through follow-up functional investigations.9,10
The causal effect of these factors on bleeding is well 
established; severe FVIII and VWF deficiencies lead to 
the bleeding disorders hemophilia A and von Willebrand 
disease, respectively. Although it is currently unclear 
whether FVIII and VWF levels causally influence the risk 
of thrombotic diseases, some genetic and observational 
evidence suggest an effect of these proteins on throm-
botic disease. Genetic variants in the F8 gene and in 3 
VWF-associated genes (ABO, STXBP5, and VWF) are ro-
bustly associated with risk of venous thrombosis, but no 
causal association has been established.11–13
The aim of this investigation was to identify new ge-
netic associations that influence plasma levels of FVIII 
and VWF by expanding the size and ancestral diversity 
of the discovery sample from previous genome-wide 
association studies (GWASs) and by improving cover-
age of the genome through the use of 1000 Genomes 
imputed data and the inclusion of chromosome X vari-
ants.14 For discoveries that reached genome-wide sig-
nificance, we conducted first-pass functional character-
ization of the candidate loci both to provide additional 
evidence of association and to better understand the 
biology regulating plasma levels of these coagulation 
phenotypes. Finally, by applying our genetic findings as 
instrument variables, we characterized the causal effect 
of plasma FVIII and VWF levels on clinical cardiovascular 
events using Mendelian randomization (MR) analyses.
METHODS
Because of patient confidentiality agreements and to comply 
with the study participants’ consent, the original data and 
study materials cannot be made available to other research-
ers for purposes of reproducing the results or replicating the 
procedure. Analytical methods will be made available on re-
quest, and summary statistics have been made publicly avail-
able through the U.S. National Library of Medicine’s National 
Center for Biotechnology Information database of Genotypes 
and Phenotypes (dbGaP).
Study Design and Participating Cohorts
This project was organized within the CHARGE Consortium 
(Cohorts of Heart and Aging Research in Genomic Epidemiology) 
Hemostasis Working Group.15 We meta-analyzed phenotype-
genotype associations of low-frequency and common (minor 
allele frequency [MAF] >0.01) variants in 32 610 individu-
als from 9 studies with FVIII levels, and in 46 354 individuals 
from 18 studies with VWF levels. A total of 20 studies con-
tributed to 1 or both of the analyses; these included partici-
pants of European, African, East Asian, and Hispanic ancestry. 
Descriptions and ancestry composition of participating cohorts 
are found in Table I in the online-only Data Supplement. All 
studies were approved by appropriate institutional review com-
mittees, and all participants gave written informed consent for 
themselves and their minor children for the use of their DNA.
Study-Level Methods
Genotype Calling and Quality Control
All participating cohorts performed genotyping using com-
mercial genotyping platforms available from Illumina or 
Affymetrix. Each study performed genotyping quality control 
checks and imputed the ≈35 million polymorphic autosomal 
and X-chromosome variants described in the 1000 Genomes 
population phase 1 version 3 for each participant using avail-
able imputation methods.16 Variant calling and quality con-
trol procedures for each cohort are described in Table I in the 
online-only Data Supplement.
Statistical Analyses
Association Analyses
Plasma FVIII activity or VWF antigen levels were measured in 
all participants (reported in percent or international units per 
Clinical Perspective
What Is New?
• Plasma coagulation factor VIII and von Willebrand 
factor concentrations are associated with risk of 
cardiovascular disease, but the genetic factors that 
control their levels are not fully understood.
• Using a multiethnic meta-analysis of genome-wide 
association studies, we identified 7 genome-wide 
significant novel associations for factor VIII and 11 
for von Willebrand factor.
What Are the Clinical Implications?
• We evaluated the effect of genetic variants with 
coronary artery disease, ischemic stroke, and ve-
nous thrombosis through mendelian randomization 
analyses and found evidence of a causal effect of 
factor VIII activity levels on venous thrombosis and 
coronary artery disease risk, and a causal effect of 
plasma von Willebrand factor levels on stroke risk.
• Our findings suggest that factor VIII and von Wil-
lebrand factor may be potential therapeutic targets 
to prevent thrombotic events.
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milliliter x 100). Participants with plasma FVIII or VWF levels 
(or activity levels) 3 standard deviations (SDs) above or below 
the population mean were removed, as were individuals on 
anticoagulation therapy. Natural log–transformed FVIII activity 
and VWF antigen levels (percent or international units per 
milliliter x 100) were analyzed separately within each study. 
Study-specific regression analyses using an additive model 
of inheritance were performed for imputed variant dosages 
and phenotype levels, adjusting for sex, age, study design 
variables, and population substructure using principal compo-
nents. All analyses were stratified by ancestry and then meta-
analyzed. X-chromosome variants were additionally stratified 
by sex, with dosage values for male subjects coded as 0/2.
Quality Control
Study-specific findings were uploaded centrally, and a quality-
control pipeline of all individual studies before meta-analysis 
was conducted with the EasyQC software package.17 Variants 
with β or standard error values >5 or imputation values <0.3 
were excluded from the analysis. Estimated minor allele 
counts calculated for all single nucleotide polymorphisms 
(SNPs) were a function of allele frequency, total number of 
samples per cohort, and imputation quality; values <10 were 
excluded from analysis. Alleles were harmonized according to 
the 1000 Genomes phase 1 version 3 reference panel, and 
duplicated SNPs or SNPs that had inconsistencies with the ref-
erence were excluded.
Meta, Transethnic, and Multiphenotype Discovery 
Analyses
Meta-analyses were performed in METAL within each an-
cestry group using a fixed-effects inverse-variance–weighted 
approach and then combined in a transethnic analysis using the 
same method.18 The transethnic analyses are presented as dis-
covery results, and we used the ancestry-specific analyses to in-
form and interpret these signals. An association was considered 
genome-wide statistically significant at a value of P<2.5×10−8 to 
correct for the low-frequency variants that were not included in 
the initial generation of GWASs,19 and only variants that passed 
quality control in at least 3 cohorts were reported. Variants with 
MAF <1% were filtered out after the meta-analyses. A genomic 
control coefficient was computed for each discovery cohort and 
was used to correct for cryptic relatedness. Finally, a locus was 
defined as ±1 Mb from the SNP with the lowest P value, and 
the SNP with the lowest P value was selected to represent the 
locus. Multiphenotype methods are described in the Methods 
in the online-only Data Supplement.
Functional Characterization of Candidate 
Loci Through Gene Silencing
In the absence of replication cohorts, we conducted first-pass 
functional characterization of the candidate loci to provide 
additional evidence of association. For each genome-wide 
significant locus, we selected candidate genes that could 
be responsible for the observed associations. Selection was 
based on proximity to the most associated SNPs in each re-
gion, information from public databases on putative effect 
of the SNPs in terms of regulation of expression and func-
tion of nearby genes, and hypothesized biological mecha-
nisms to regulate VWF/FVIII. This selection process identified 
1 to 3 candidate genes for each associated locus. To screen 
for functionality, human umbilical vein endothelial cells 
(Life Line Cell Technology) were plated on collagen-coated 
96-well plates and transfected with small interfering RNA 
(siRNA)  siRNA (Silencer Select, Thermo Fisher Scientific) 
directed against the candidate genes using the transfection 
reagent oligofectamine (Thermo Fisher Scientific). Cells were 
cultured for 4 days after transfection, and media was then 
replaced with control media or media containing 10 µmol/L 
histamine for 30 minutes to stimulate an inflammatory re-
sponse. The FVIII and VWF in the media were measured by an 
ELISA using antibodies from Fitzgerald Industries and had de-
tection ranges of 0.003 to 0.21 IU/mL for the FVIII assay and 
0.5 to 120 ng/μL for the VWF assay. Every experiment was 
repeated 4 times, and results are expressed as the mean±SD 
of the relative expression compared with a negative control 
(transfected with scramble siRNA).
Follow-Up Genetic Analyses
Conditional Analyses
To identify additional independent genetic signals at the as-
sociated loci, we used an approximate method implemented 
in Genome-Wide Complex Trait Analysis (GCTA tool) for con-
ditional and joint analysis using meta-analysis summary sta-
tistics.20 We used best-guess imputation for variants with 
imputation quality >0.3 in 8481 European-ancestry individuals 
from the FHS (Framingham Heart Study) as the reference panel. 
A description of the FHS is given in the Methods in the online-
only Data Supplement. To prevent spurious conditional associa-
tions arising from a discrepancy between linkage disequilibrium 
in our GWAS and the reference panel, we also performed the 
conditional analysis on the results of the European-ancestry 
meta-analysis as a sensitivity analysis, because different genetic 
variants showed the strongest association in the transethnic 
analysis compared with the European-only analysis.
Mendelian Randomization
For the sentinel variant in each locus in FVIII and VWF analy-
ses, we conducted in silico lookups for the associations of 
each individual variant with 3 major cardiovascular events: 
coronary artery disease (CAD) in the CARDIOGRAMplusC4D 
Consortium,21,22 ischemic stroke (IS) in the MEGASTROKE anal-
ysis within the International Stroke Genetics Consortium,23 
and venous thromboembolism (VTE) in the INVENT 
Consortium (International Network on Venous Thrombosis).11 
We conducted 2-sample MR analyses to detect any potential 
causal effects of plasma FVIII and VWF levels on each cardi-
ovascular outcome separately. We used summary statistics to 
generate 1 causal estimate per significant locus as the ratio of 
the association of the variant with disease to the association 
of the variant with the exposure, and estimates were then 
meta-analyzed using an inverse-variance–weighted approach 
as our primary MR estimate, known as the inverse-variance–
weighted estimate.24 Additional methods to avoid bias result-
ing from heterogeneity and the final variants composing the 
instrumental variables are described further in the Methods 
and Tables II through IV in the online-only Data Supplement. 
Because FVIII plasma levels are determined largely by VWF 
plasma levels owing to the carrier role of VWF for FVIII in 
plasma, essentially all genetic predictors of plasma VWF levels 
are also predictors of FVIII plasma levels. The inverse, however, 
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is not true, and a small subset of variants predict FVIII plasma 
levels without predicting VWF levels. To investigate the inde-
pendent causal role of FVIII plasma levels from that of VWF 
plasma levels on cardiovascular disease events, we applied a 
multivariable MR approach in which we adjusted for VWF var-
iant effects in the estimate of causal association between FVIII 
and cardiovascular disease outcomes.25
RESULTS
FVIII, VWF, and Multiphenotype Meta-
Analyses
Agnostic Discovery
Data used for FVIII meta-analysis was available from 
25 897 European ancestry, 4500 African ancestry, 773 
East or Indian Asian ancestry, and 1440 Hispanic par-
ticipants. Transethnic meta-analysis for FVIII resulted in 
13 887 196 variants passing all filters and identified 1431 
variants that reached genome-wide statistical significance 
at 11 loci. Data used for VWF were available from 42 379 
European ancestry, 3700 African ancestry, and 275 His-
panic participants. Meta-analysis for VWF resulted in 
10 537 485 variants passing all filters and identified 2453 
genome-wide significant variants at 17 loci (Figure  1A 
and 1B). European-specific meta-analysis identified 1 sig-
nificant variant at 1 additional locus. Analysis using com-
bined FVIII and VWF phenotypes (Methods in the online-
only Data Supplement) identified 2828 variants reaching 
genome-wide significance at 2 additional loci, which 
were not identified in single-phenotype analyses.
Figure 1.  Manhattan plot for the trans-
ethnic analyses factor VIII (FVIII) and von 
Willebrand factor (VWF).  
Representation of genome-wide results for FVIII 
(A) and VWF (B). Loci named by closest gene. 
Black indicates novel associations.
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Table 1 shows the genetic discovery results for the FVIII, 
VWF, and combined FVIII-VWF phenotypes. Overall, 23 u-
nique loci were identified. Among these, 13 were new 
associations not previously reported. Among the newly 
identified loci, 7 were associated with FVIII levels (FCHO2/
TMEM171/TNPO1, HLA, SOX17/RP1, LINC00583/NFIB, 
RAB5C/KAT2A, RPL3/TAB1/SYNGR1/PDGB, and ARSA), 
and 11 were associated with VWF levels (PDHB/PXK/
KCTD6, SLC39A8, FCHO2/TMEM171/TNPO1, HLA, GI-
MAP7/GIMAP4, OR13C5/NIPSNAP, DAB2IP, C2CD4B, 
RAB5C/KAT2A, RPL3/TAB1/SYNGR1/PDGB, and ARSA). 
Figure IA through IN in the online-only Data Supplement 
shows regional plots for the novel loci plotted for the 2 
phenotypes. The lowest MAF for the index variant was 
0.02, whereas the effect size per allele ranged from 
0.015 to 0.032 (in log-transformed units) for FVIII levels 
and from 0.014 to 0.060 for VWF levels.
Among the 23 genome-wide significant findings, 
10 loci were previously reported to be associated with 
plasma levels of FVIII, VWF, or both: STXBP5, SCARA5, 
ABO, ST3GAL4, STAB2, STX2, VWF, TCN2, CLEC4M, 
and TMLHE-F8 region.
Conditional Analyses and Variant 
Characterization
In follow-up analyses, we conditioned on sentinel vari-
ants to determine whether secondary independent 
genome-wide significant signals were present. Results 
and additional independent variants are summarized in 
Table 2, along with findings from in silico investigations 
of the putative functional variant, and in Tables V and 
VI in the online-only Data Supplement. SCARA5, ABO, 
VWF, and STAB2 were predicted to have >1 independ-
ent signal both for FVIII and VWF analyses (details in 
Methods and Tables V and VI in the online-only Data 
Supplement), some of which are in agreement with 
previous publications.6 Among the independently asso-
ciated variants within the ABO locus, SNPs rs10901252 
and rs687621 perfectly discriminate B and O blood 
groups from A, and rs8176685 can reasonably capture 
information to tag A1/A2 (r2 0.59/D’ 0.99 with the tag 
SNP), confirming that ABO blood groups are essential 
determinants of VWF and FVIII plasma levels.
Variance Explained
Overall, the top variants for these loci (including the 
strongest independent associated variants in each lo-
cus that reached genome-wide significance after condi-
tional analyses) explain 17% of the phenotypic variance 
for FVIII and 21.3% of the variance for VWF. ABO locus 
was by far the strongest determinant, alone explaining 
13.6% and 16.2% of these variances, respectively.
Functional Analyses
We silenced 21 genes across 12 loci to assess the 
in vitro impact on FVIII and VWF secretion (Fig-
ure  2A and 2B). These include the main candidate 
genes identified by proximity (Table  1). Our results 
suggest that 10 of the 12 candidate loci had ≥1 
genes that changed VWF levels in media under ba-
sal or histamine-stimulated conditions. Specifically, 
silencing PDHB, SLC39A8, TMEM171, TNPO1, HLA-
C, GIMAP7, NIPSNAP3A, NIPSNAP3B, C2CD4B, and 
SYNGR1 increased VWF release into media under ba-
sal conditions, whereas ST3GAL4 silencing decreased 
VWF secretion. When cells were stimulated with his-
tamine, silencing TMEM171, TNPO1, HLA-C, SNIP-
SNAP3A (but not SNIPSNAP3B), C2CD4B, KAT2A, 
and TAB1 increased VWF release in the media, and 
RAB5C decreased VWF secretion (Table  1 and Fig-
ure 2A and 2B). For the experiments on the 5 genes 
that were shown to be associated only with FVIII lev-
els (LINC00583, NFIB, SOX17, RP1, and TMLHE-F8), 
we could not find detectable levels of FVIII in media 
from treated human umbilical vein endothelial cells, 
and therefore, the experiments were inconclusive.
MR Analyses and Cardiovascular Events
Figure 3 shows forest plots representing the results from 
MR analyses. We first analyzed FVIII and VWF individu-
ally using the inverse-variance–weighted estimates that 
included the sentinel variant in each locus (after exclu-
sion of variants with pleiotropic effects; Tables II through 
IV in the online-only Data Supplement). Both VWF and 
FVIII plasma levels showed a significant causal effect on 
CAD, IS, and VTE risk. For CAD, the odds ratios (ORs) 
associated with a per 1-SD change in natural log–trans-
formed FVIII and VWF were 1.15 (95% CI, 1.05–1.27) 
and 1.14 (95% CI, 1.05–1.23), respectively. For IS, the 
ORs were 1.28 (95% CI, 1.14–1.43) and 1.19 (95% CI, 
1.10–1.29), respectively. For VTE, the ORs were 2.75 
(95% CI, 2.14–3.55) and 2.31 (95% CI, 1.89–2.81), 
respectively. Sensitivity analyses using both MR-Egger 
regression and weighted median estimates support the 
inverse-variance–weighted estimates, and no significant 
pleiotropic effect was evident after exclusion of the plei-
otropic loci (Figure 3 and Table III and Figure IIA through 
IIC in the online-only Data Supplement).
We then performed multivariable MR analyses of the 
FVIII phenotype to identify causal effects of FVIII activity 
levels that were independent of VWF levels. For VTE and 
CAD outcomes, after adjustment of FVIII results by the 
effect of VWF, the ORs were modestly attenuated (20% 
and 16%, respectively) compared with the unadjusted 
estimates and CIs widened. For IS, however, adjustment 
of FVIII results by the effect of VWF resulted in an 86% 
attenuation of the OR to 0.88 (95% CI, 0.51–1.51). We 
could not demonstrate a causal association of VWF levels 
with VTE and CAD that was independent of FVIII levels.
Of note, both the ABO and HLA loci were excluded 
from the instrumental variables for the MR analyses 
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Table 1. Main Association Results for FVIII and VWF Transethnic GWAS Meta-Analysis
rsID
Effect
Allele
Other
Allele
Freq 
FVIII
N
FVIII
β 
FVIII
P Value
FVIII
Freq 
VWF
No.
VWF
β 
VWF
P Value
VWF
Closest 
Gene(s) Association
VWF Release at 
B and on S for 
Candidate Loci
rs55954186 a g 0.36 35 513 0.011 2.2E−05 0.37 46 229 0.015 5.2E−09 PDHB, PXK, 
KCTD6
New PDHB (B=↑**; S=NS), 
PXK (B=NS; S=NS), 
KCTD6 (B=NS; S=NS)
rs6855246 a g 0.93 35 513 −0.003 0.672 0.92 46 068 −0.034 8.68E−10 SLC39A8† New SLC39A8 (B=↑**)
rs548630 a c 0.49 36 286 −0.016 2.1E−10 0.47 46 137 −0.018 1.2E−12 FCHO2, 
TMEM171, 
TNPO1
New FCHO (B=NS; S=NS), 
TMEM171 (B=↑***; 
S=↑*), TNPO1 
(B=↑***; S=↑**)
rs9390460 t c 0.47 36 286 −0.019 2.2E−15 0.46 46 212 −0.033 5.6E−42 STXBP5 Known …
rs9271597‡ a t 0.41 28 203 −0.015 1.4E−08 0.41 31 364 −0.012 2.1E−04 HLA region New HLA-C 
(B=↑**;s=↑***)
rs7788962 a g 0.62 33 773 −0.010 2.3E−04 0.61 46 231 −0.014 7.3E−09 GIMAP7, 
GIMAP4
New GIMAP7 (B=↑***; 
S=NS), GIMAP4 
(B=NS; S=NS)
rs4276643 t c 0.66 36 286 −0.023 1.3E−19 0.67 44 168 −0.029 8.8E−28 SCARA5 Known …
rs10102164 a g 0.19 36 286 0.019 2.4E−09 0.20 46 230 0.009 2.9E−03 SOX17,  
RP1
New Too little FVIII released 
by endothelial cells to 
be detected in vitro
rs6479259 t c 0.73 28 535 −0.021 1.1E−03 0.73 24 987 −0.056 1.5E−08 OR13C5, 
NIPSNAP§
New NIPSNAP3A (B=↑*; 
S=↑**), NIPSNAP3B 
(B=↑*; S=NS)
rs10985344 a g 0.25 36 286 0.011 7.5E−05 0.25 46 178 0.017 3.5E−09 DAB2IP New DAB2IP (B=NS; S=NS)
rs687289 a g 0.36 36 286 0.145 1.9E−770 0.33 46 231 0.197 5.0E−1443 ABO Known …
9:13930481:ID d i 0.85 22 480 −0.032 2.7E−10 0.85 29 409 −0.003 4.4E−01 LINC00583, 
NFIB
New Too little FVIII released 
by endothelial cells to 
be detected in vitro
rs35458154 a g 0.03 33,871 0.048 3.1E−08 0.03 44 020 0.060 3.0E−12 ST3GAL4 Known‖ ST3GAL4 (B=↓**; 
S=NS)
rs4981022 a g 0.69 36 286 0.025 3.0E−20 0.69 46 232 0.035 6.6E−41 STAB2 Known …
rs4759787 a c 0.40 36 286 0.011 1.1E−05 0.37 46 180 0.023 7.7E−20 STX2 Known …
rs2238109 a t 0.39 36 286 0.026 3.5E−24 0.38 46 232 0.050 1.8E−89 VWF Known …
rs4904820 a g 0.49 36 286 0.014 1.8E−08 0.47 46 232 0.022 6.0E−19 TCN2 Known …
rs6494314 t c 0.18 36 286 −0.007 2.4E−02 0.17 46 232 −0.018 1.1E−08 C2CD4B New C2CD4B (B=↑*; 
S=↑**)
rs1869365   Significant in combined multiphenotype analysis <5.0E−8 RAB5C, 
KAT2A
New RAB5C (B=NS; S=↓*), 
KAT2A (B=NS; S=↑**)
rs2277998 a g 0.30 33 097 −0.010 4.4E−04 0.30 45 566 −0.022 6.5E−16 CLEC4M Known …
rs5750823¶ t c 0.70 36 286 −0.013 1.5E−06 0.72 46 230 −0.020 6.0E−14 RPL3, 
TAB1, 
SYNGR1, 
PDGB
New TAB1 (B=NS; S=↑**), 
SYNGR1 (B=↑*; 
S=NS), PDGFB (B=NS; 
S=NS)
rs9616897   Significant in combined multiphenotype analysis <5.0E−8 ARSA New ARSA (B=NS; S=NS)
rs150926226# c g 0.62 20 537 0.017 3.3E−09 0.65 28 685 −0.005 7.0E−02 TMLHE, F8 Known Too little FVIII released 
by endothelial cells to 
be detected in vitro
B indicates baseline; FVIII, factor VIII; Freq, allele frequency of the effect allele; NS, not significant; rsID, rs identify of unique variant; S, stimulated; and VWF, von 
Willebrand factor. β and frequency refer always to the effect allele, and they are expressed as natural log–transformed values from the original units (reported in 
percent or international units per milliliter times 100 U). No functional work was performed in known genes, and these are indicated by “…” in the last column.
*P<0.05; **P<0.01; ***P<0.001.
†SLC39A8 was found in VWF meta-analysis of European ancestry only (n=42 145).
‡Although not in linkage disequilibrium with this variant, a low-frequency variant 665 kb upstream of rs9271597 was found significantly associated to VWF levels 
(rs80082277; P=1×10−8), and we consider it within the HLA region; thus, we pursued this gene for further functional validation.
§Olfactory receptor family was not considered for further functional validation for its low expression in the relevant tissues (mainly artery and whole blood).
‖The ST3GAL4 locus was new at the time of analyses, although reported in a recent candidate gene study lacking replication.26
¶The highest associated single nucleotide polymorphism in this locus for FVIII is rs137631 (P=9.5×10−9), located close to RPL3 gene, 112 kb downstream of the 
TAB1/SYNGR1 locus, and in low linkage disequilibrium with rs5750823 (R2=0.14)
#Chromosome X variant for VWF available only for European-ancestry samples (n=28 685).
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Table 2. Characteristics of All Associated Independent Variants After Conditional Analyses
Marker Name rsID
Closest 
Gene(s)
Variant 
Position
Putative 
Functional
EUR-only TRANS-ethnic
Top Meta 
Variant
LD* 
(R2)
LD* 
(D’)
Original  
P Value
Conditional 
P Value
Original  
P Value
Conditional 
P Value
FVIII (n=29 573 EUR; n=36 286 TRANS)
5:72406659 rs548630 TNPO1; 
FCHO2; 
TMEM171
9.5 kb 5’ 
TMEM171
… 5.14E−10 3.96E−10 2.10E−10 2.06E−10 5:72406659 Top 
variant
Top 
variant
6:147701217 rs9390461 STXBP5 Intronic rs1039084, 
missense
2.74E−13 4.06E−13 1.73E−14 … 6:147703299 0.98 1.00
6:147703299 rs9399599 STXBP5 Intronic rs1039084, 
missense
3.73E−13 … 1.41E−15 4.70E−16 6:147703299 Top 
variant
Top 
variant
8:27778148 rs55829013 SCARA5 Intronic … 3.39E−10 8.54E−10 5.81E−10 … 8:27805815 0.51 0.77
8:27823832 rs11780263 SCARA5 Intronic … 3.41E−17 6.96E−17 1.39E−19 … 8:27805815 0.10 0.98
8:27805815 rs7816579 SCARA5 Intronic SiPhy 
conserved
5.32E−16 … 6.52E−21 4.07E−21 8:27805815 Top 
variant
Top 
variant
8:55421614 rs10102164 SOX17; 
RP1
Intergenic … 1.66E−07 … 2.38E−09 2.44E−09 8:55421614 Top 
variant
Top 
variant
9:13930481:ID rs35468074 LINC00583 Intronic … 1.74E−10 1.24E−10 2.66E−10 3.10E−10 9:13930481:ID Top 
variant
Top 
variant
9:136116662 rs11793768 ABO 14 kb 3’ 
ABO
… 3.74E−13 1.29E−62 2.16E−13 … 9:136132908:ID 0.08 0.72
9:136137065 rs687621 ABO Intronic … 1.18E−647 <1E−320 6.85E−778 … 9:136132908:ID 0.89 0.98
9:135976698 rs35108384 ABO Intronic … 4.58E−12 … 2.24E−12 6.53E−12 9:136132908:ID 0.00 0.14
9:136114000 rs78490142 ABO 17 kb 3’ 
ABO
… 1.12E−03 … 6.53E−05 1.48E−13 9:136132908:ID 0.01 1.00
9:136132908:ID rs8176719 ABO Intronic SiPhy 
conserved
1.62E−307 … 3.52E−403 P<1E−320 9:136132908:ID Top 
variant
Top 
variant
9:136178821 rs574237 ABO Intergenic … 2.89E−29 … 6.94E−38 5.38E−26 9:136132908:ID 0.01 0.18
9:136181539 rs551924 ABO Intergenic … 2.81E−48 … 9.21E−75 2.20E−63 9:136132908:ID 0.00 0.14
9:136207218 rs607900 ABO Intergenic rs116779216, 
missense 
SURF1
6.86E−03 … 3.21E−15 1.85E−13 9:136132908:ID 0.00 0.19
9:136255149 rs62575992 ABO Intergenic … 3.46E−42 … 8.45E−45 1.83E−26 9:136132908:ID 0.02 0.80
9:136344853 rs3124758 ABO Intergenic … 2.71E−21 … 1.74E−18 5.88E−15 9:136132908:ID 0.00 0.14
12:6062894 rs57040304 VWF Intronic rs7962217, 
missense, SiPhy 
conserved
1.51E−15 1.22E−14 7.71E−12 … 12:6160614 0.00 0.09
12:6160614 rs7135039 VWF Intronic rs1063856, 
missense
3.00E−19 7.02E−18 2.32E−24 7.21E−20 12:6160614 Top 
variant
Top 
variant
12:6070845 rs12423482 VWF Intronic rs7962217, 
missense, SiPhy 
conserved
2.49E−15 … 2.92E−18 1.57E−17 12:6160614 0.00 0.15
12:6160146 rs11064010 VWF Intronic … 8.36E−07 … 2.41E−11 2.51E−09 12:6160614 0.01 0.33
12:104000319 rs1070073 STAB2 Intronic … 1.07E−13 5.04E−13 2.25E−14 … 12:104149874 0.00 0.16
12:104147207 rs3751198 STAB2 Intronic … 2.16E−17 5.91E−17 5.88E−18 … 12:104149874 0.70 0.98
12:104000470 rs2723889 STAB2 Intronic … 1.08E−13 … 2.14E−14 1.21E−14 12:104149874 0.00 0.16
12:104149874 rs4981022 STAB2 Intronic … 1.16E−17 … 2.95E−20 4.47E−21 12:104149874 Top 
variant
Top 
variant
14:92268531 rs10498631 TC2N Intronic … 6.69E−09 8.63E−09 2.30E−08 … 14:92302972 0.54 0.82
14:92302972 rs58204830 TC2N Intronic … 2.57E−08 … 6.28E−09 7.03E−09 14:92302972 Top 
variant
Top 
variant
22:39717706 rs137631 RPL3 1.3 kb 5’ 
of RPL3
… 2.35E−07 … 9.48E−09 1.34E−08 22:39717706 Top 
variant
Top 
variant
X:154721357 rs150926226 TMLHE,F8 … … … † 3.25E−09 † X:154721357 … …
(Continued )
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3:58383174 rs55692656 PXK; 
KCTD6; 
PDHB
Intronic 
PXK
rs56384862, 
missense PXK; 
rs34579268 
missense PXK; 
rs200687616 
frameshift 
PDHB
6.48E−09 1.01E−08 3.33E−08 … 3:58436476 0.94 1.00
3:58436476 rs55954186 PXK; 
KCTD6; 
PDHB
17 kb 3’ of 
PXK
rs56384862, 
missense PXK; 
rs34579268 
missense PXK; 
rs200687616 
frameshift 
PDHB
8.72E−09 … 5.20E−09 8.06E−09 3:58436476 Top 
variant
Top 
variant
5:72403453 rs7733340 TNPO1; 
FCHO2; 
TMEM171
Intergenic … 5.80E−13 1.52E−12 3.40E−12 … 5:72406659 0.93 0.99
5:72406659 rs548630 TNPO1; 
FCHO2; 
TMEM171
9.5 kb 5’ 
TMEM171
… 1.33E−12 … 1.22E−12 6.19E−13 5:72406659 Top 
variant
Top 
variant
6:31192766 rs9263993 HLA region Intergenic … 8.54E−09 3.50E−09 1.69E−07 … 6:31925848 0.00 0.63
6:31941629 rs116420479 HLA region Intronic 
STK19
… 3.10E−08 1.49E−08 1.02E−08 … 6:31925848 0.94 0.98
6:31158633 rs9263861 HLA region Intergenic … 3.08E−08 … 3.25E−08 8.64E−09 6:31925848 0.00 1.00
6:31906828 rs78593564 HLA region Intronic C2 … 3.15E−08 … 1.03E−08 2.76E−09 6:31925848 1.00 1.00
6:147694334 rs9390460 STXBP5 Intronic rs1039084, 
missense
6.32E−38 1.67E−38 5.58E−42 1.27E−42 6:147694334 Top 
variant
Top 
variant
7:150296496 rs13230842 GIMAP7; 
GIMAP4
Intergenic … 2.06E−08 1.96E−08 2.95E−08 … 7:150227227 0.18 0.97
7:150227227 rs7788962 GIMAP7; 
GIMAP4
9.1 kb 3’ 
of GIMAP7
… 6.29E−08 … 7.30E−09 1.36E−08 7:150227227 Top 
variant
Top 
variant
8:27803599 rs4276643 SCARA5 Intronic … 5.77E−27 1.19E−29 8.77E−28 7.69E−31 8:27803599 Top 
variant
Top 
variant
8:27815481 rs62496810 SCARA5 Intronic … 3.74E−08 4.38E−11 4.98E−08 6.04E−11 8:27803599 0.02 1
9:124416940 rs10985344 DAB2IP Intronic … 4.11E−09 3.76E−09 3.47E−09 … 9:124416940 Top 
variant
Top 
variant
9:124421965 rs4837886 DAB2IP Intronic … 3.84E−09 … 4.43E−09 3.94E−09 9:124416940 0.79 0.97
9:135919501 rs138796740 ABO Intergenic … 2.61E−08 7.06E−11 3.59E−08 … 9:136132908:ID 0.00 0.15
9:136128546 rs7857390 ABO 2.5 kb 3’ 
of ABO
… P<1E−320 7.81E−294 2.15E−393 … 9:136132908:ID 0.36 1
9:136145414:ID rs202001822 ABO Intronic … 5.90E−78 1.46E−39 2.26E−80 … 9:136132908:ID 0.10 1
9:136147553 rs660340 ABO Intronic … P<1E−320 P<1E−320 1.11E−492 … 9:136132908:ID 0.33 0.87
9:136177394 rs656105 ABO Intergenic … 1.20E−66 2.62E−129 4.23E−73 … 9:136132908:ID 0.02 0.19
9:136128000 rs10901252 ABO 3.1 kb 3’ 
of ABO
rs8176747, 
missense; 
rs8176746, 
missense; 
rs8176743 
missense
1.78E−291 … 2.61E−351 P<1E−320 9:136132908:ID 0.16 0.99
9:136130677 rs62641786 ABO 3’ UTR … 2.79E−96 … 2.59E−106 8.85E−30 9:136132908:ID 0.03 0.91
9:136138765:ID rs8176685 ABO Intronic … P<1E−320 … 5.95E−507 P<1E−320 9:136132908:ID 0.31 1
9:136316367 rs28680325 ABO Intronic 
ADAMTS13
… 1.04E−09 … 2.88E−10 1.12E−09 9:136132908:ID 0.01 0.25
Table 2. Continued
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P Value
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P Value
Original  
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because of evidence of pleiotropic effects shown in 
the heterogeneity tests (Table III in the online-only 
Data Supplement). When we estimated causal effects 
using ABO alone as an instrument, estimates of causal 
effects were essentially the same across phenotypes 
and outcomes: OR of 2.57 (95% CI, 2.47–2.67) for 
FVIII and VTE, 2.28 (95% CI, 2.18–2.38) for VWF and 
VTE, 1.10 (95% CI, 1.06–1.14) for FVIII and IS, 1.09 
(95% CI, 1.05–1.13) for VWF and IS, 1.10 (95% CI, 
1.06–1.14) for FVIII and CAD, and 1.08 (95% CI, 
1.04–1.12) for VWF and CAD.
DISCUSSION
In the present study, we meta-analyzed data from 
>36 000 individuals with FVIII levels and >46 000 
with VWF and identified 13 novel loci, of which 
7 associated with FVIII plasma levels and 11 asso-
ciated with VWF levels. Overall, new discoveries 
yielded an additional 6.2% and 8.1% proportion of 
variance explained for FVIII and VWF, respectively, 
from previous estimations,8 and suggest that a great 
proportion of the genetic variance is explained by 
common variation. Furthermore, we presented ex-
perimental evidence of biological function on VWF 
regulation for 14 of these genes from gene silencing 
in vitro: PDHB, SLC39A8, TMEM171, TNPO1, HLA-
C, GIMAP7, NIPSNAP3A, NIPSNAP3B, ST3GAL4, 
C2CD4B, RAB5C, KAT2A, TAB1, and SYNGR1. Fi-
nally, we provide evidence in support of a causal 
role of FVIII levels on VTE and CAD events and of 
VWF levels on IS events.
11:126296825 rs35458154 ST3GAL4 Intronic … 6.35E−12 8.31E−12 2.96E−12 2.42E−12 11:126296825 Top 
variant
Top 
variant
12:6157394 rs2283335 VWF Intronic rs1063856, 
missense
6.48E−83 5.55E−79 2.08E−89 … 12:6153967 1 1
12:6160146 rs11064010 VWF Intronic … 1.60E−27 8.75E−22 7.90E−27 2.40E−21 12:6153967 0.01 0.30
12:6225931 rs112814955 VWF Intronic … 1.43E−42 3.14E−49 9.02E−43 4.00E−50 12:6153967 0.01 0.34
12:6153967 rs2238109 VWF Intronic rs1063856, 
missense
1.37E−82 … 1.77E−89 3.41E−87 12:6153967 Top 
variant
Top 
variant
12:104000319 rs1070073 STAB2 Intronic … 2.28E−36 8.23E−31 2.03E−36 6.72E−32 12:104149874 0.00 0.16
12:104007418 rs11111679 STAB2 Intronic 2.31E−14 4.79E−10 1.22E−14 1.60E−10 12:104149874 0.00 0.02
12:104127353 rs73192004 STAB2 Intronic rs17034433, 
missense
2.29E−08 2.33E−08 5.09E−09 6.57E−09 12:104149874 0.01 0.53
12:104149874 rs4981022 STAB2 Intronic … 5.44E−37 4.69E−41 6.57E−41 8.65E−45 12:104149874 Top 
variant
Top 
variant
12:131287011 rs6486599 STX2 Intronic rs17564, 
missense
4.23E−18 1.92E−18 1.14E−18 … 12:131290180 1.00 1
12:131290180 rs4759787 STX2 Intronic rs17564, 
missense
4.45E−18 … 7.73E−20 3.84E−20 12:131290180 Top 
variant
Top 
variant
14:92290744 rs10498632 TCN2 Intronic … 2.58E−18 4.74E−18 5.00E−18 - 14:92318935 0.53 0.99
14:92318935 rs4904820 TCN2 Intronic … 8.30E−18 … 6.04E−19 2.40E−19 14:92318935 Top 
variant
Top 
variant
15:62455019 rs6494314 C2CD4B 700 bp 3’ 
of gene
rs8040712, 
missense
9.63E−08 … 1.14E−08 1.30E−08 15:62455019 Top 
variant
Top 
variant
19:7831628 rs2277998 CLEC4M Missense rs2277998, 
missense
2.02E−15 7.30E−16 6.47E−16 1.74E−15 19:7831628 Top 
variant
Top 
variant
22:39790191 rs2413590 PFGFB; 
SYNGR1; 
TAB1
5.6 kb of 
TAB1
… 3.96E−12 4.44E−12 2.02E−12 … 22:39829973 0.75 0.94
22:39829973 rs5750823 PFGFB; 
SYNGR1; 
TAB1
Intronic 
TAB1
… 2.98E−11 … 5.95E−14 7.58E−14 22:39829973 Top 
variant
Top 
variant
Original P value is the P value from discovery meta-analysis. The putative functional column indicates the best candidate variant in high LD with the associated 
variant (R2>0.8) that has been identified in silico as the best candidate variant to have an impact on the adjacent gene/genes. EUR indicates European; FVIII, factor 
VIII; LD, linkage disequilibrium; TRANS, transethnic; UTR, untranslated region; and VWF, von Willebrand factor.
*LD with top variant in the region, calculated with Framingham Heart Study data. 
†Primary single nucleotide polymorphism was not well imputed in Framingham Heart Study, and no other single nucleotide polymorphisms in the region achieved 
genome-wide significance in conditional analyses. Ellipses indicate that conditional analyses were not performed.  
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Characterization of the Novel Loci 
Regulating FVIII and VWF
As expected for traits with strong genetic correla-
tion, most of the newly associated loci regulate both 
FVIII and VWF levels in blood. Our results show that 
most of the highest signal-independent variants as-
sociated with these traits were located in introns or 
noncoding regions, although a substantial proportion 
were in strong linkage disequilibrium (R2>0.8) with 
mutations causing missense or frameshift mutations 
in the nearby genes (Table 2 and Table VII in the on-
line-only Data Supplement). We also explored expres-
sion quantitative trait loci associations using publicly 
available data, and we conducted pathway analyses 
for the novel loci. See the Methods and Tables VIII 
through XIII in the online-only Data Supplement for 
this information.
For most loci, several genes were identified within 
the associated region, and we selected ≥1 genes for 
further characterization using in vitro cell models. On 
the basis of our initial functional characterization, ≥1 
plausible culprit genes regulating VWF secretion could 
be isolated at most loci. Several candidate genes that 
showed a clear change in VWF levels on silencing have 
been shown to participate in vesicle trafficking and ex-
ocytosis, as well as intracellular signaling and inflam-
matory response. The most relevant functional genes 
are described below and summarized in Figure III in the 
online-only Data Supplement.
VWF Biogenesis, Vesicle Trafficking, and 
Secretion
ST3GAL4 is a Golgi transferase that catalyzes transfer 
of sialic acids in VWF glycan branches that are essen-
tial to its biogenesis, adhesive activity, and clearance.26 
It also has a role in clearance of desialylated platelets 
with effects on platelet homeostasis. Genetic variants 
in ST3GAL4 locus have been associated with total cho-
lesterol, low-density lipoprotein cholesterol, alkaline 
phosphatase, increased platelet aggregation, fibrino-
gen, C-reactive protein, and CAD (see further details 
and references in Table VII in the online-only Data Sup-
plement). Our functional analyses showed a substantial 
reduction of VWF release on ST3GAL4 silencing, which 
strengthens the evidence of this gene as a novel VWF 
regulator in basal conditions.
SYNGR1 encodes an integral membrane protein 
associated with presynaptic vesicles in neuronal cells. 
Several commonalities have been described between 
the exocytic machinery that drives vesicle trafficking 
and membrane fusion in endothelial cells and synaptic 
machinery found in neurons,27,28 which suggests that 
SYNGR1 could have a role in vesicle trafficking and exo-
cytosis of VWF from the Weibel-Palade bodies. Genetic 
variation in this locus has also been associated with IgG 
glycosylation, rheumatoid arthritis, and inflammatory 
bowel disease/Crohn disease, the last 2 consistent with 
an effect of deregulation of interleukin and inflamma-
tory signaling pathways.
NIPSNAP3A and NIPSNAP3B were selected as the 
main biologically plausible genes for locus on chromo-
some 9, and results from the functional study show 
evidence of significant upregulated levels of VWF on 
silencing of either gene. Again, a reported role of these 
genes in vesicular trafficking29 suggests that these 
genes could be important in Weibel-Palade formation 
and exocytosis of VWF, both in basal conditions and 
under inflammatory stimuli.
Among the 2 new loci found in the transethnic mul-
tiphenotype analysis, RAB5C is particularly interesting. 
It is a member of the Rab protein family, thought to 
ensure fidelity in the process of docking and fusion 
of vesicles with their correct acceptor compartment,30 
which may be relevant to the process of fusion of Wei-
bel-Palate vesicles to release VWF in endothelial cells. 
RAB5C silencing caused a significant decrease of VWF 
release in media of endothelial cells on stimulation 
with histamine.
Our in vitro cell work showed a significantly increased 
VWF secretion on PDHB silencing. PDHB codes for a 
subunit of the pyruvate dehydrogenase complex, which 
converts pyruvate to acetyl-CoA in the mitochondrion. 
Figure 2. Silencing candidate genes changes basal release and stimu-
lated release of von Willebrand factor (VWF). 
Human umbilical vein endothelial cells were transfected with short interfering 
RNA (siRNA) against selected genes for 4 days; the media was changed; and 
the cells were cultured for 30 minutes for basal release (A) or were stimulated 
with histamine 10 µmol/L for 30 minutes (B). VWF was then measured in the 
supernatant by an ELISA. n=4±SD. All results are relative to VWF release after 
transfection with a scrambled control siRNA, which is set as reference (100%). 
*P<0.05. **P<0.01. ***P<0.001. 
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We speculate that it is possible that the metabolism of 
endothelial cells regulates vesicle trafficking and exocy-
tosis of VWF, meaning that the exocytosis process is de-
pendent on the energetic status of the endothelial cell. 
Genetic variation in this locus has also been associated 
with total cholesterol, systemic lupus erythematosus, 
and rheumatoid arthritis.
Intracellular Signaling and Inflammatory 
Response
TAB1 silencing increased VWF released in media in our 
in vitro functional analyses, whereas no effect could 
be seen for PDGFB, a gene that has been implicated 
in CAD and VTE risk. TAB1 is a regulatory protein that 
acts as a mediator of several intracellular signaling 
pathways, especially those mediated by transforming 
growth factor-ß, WNT-1, and interleukin-1, which sug-
gests that it might have a role mediating VWF release 
on certain cellular stimuli.
Similarly, silencing the C2CD4B gene in cultured en-
dothelial cells resulted in strong upregulation of VWF 
release both in basal conditions and under stimulus 
conditions. Allelic variants in this gene have also been 
associated with fasting glucose homeostasis and type 
2 diabetes mellitus. Transcripts of this gene are found 
predominantly in the nuclear compartment of endothe-
lial cells, and a possible role in regulation of transcrip-
tion that might increase vascular permeability in acute 
inflammation has been suggested.31 Similarly, TNPO1 
Figure 3. Mendelian randomization results.  
Results show odds ratio (OR) (95% CI) per 
every higher SD change in FVIII (A) and von 
Willebrand factor (VWF; B). CAD indicates 
coronary artery disease; CVD, cardiovascular 
disease; FVIII, factor VIII; IVW, inverse-variance–
weighted method; IVW.adjusted, IVW factor 
VIII adjusted for the effects of VWF; and VTE, 
venous thromboembolism.
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codes for a nuclear receptor (Transportin-132), which 
mediates nuclear import of several proteins, which 
could also suggest a role in regulation of transcription 
under certain circumstances.
DAB2IP is involved in several relevant cell-signaling 
pathways in response to inflammation, innate immune 
response, and cell growth inhibition, and genetic vari-
ation in this gene has been associated with abdominal 
aortic aneurysm and heart rate. Despite the strong ge-
netic signal in our data, functional confirmation could 
not be achieved for DAB2IP in our secretion experi-
ment, so additional investigative work is needed.
GIMAP7 showed a significant increase of VWF re-
lease on silencing. GTPases of immunity-associated pro-
teins are regulators of lymphocyte survival and homeo-
stasis,33 although limited data have been published on 
the function of these proteins.
Finally, although it did not reach genome-wide sig-
nificance in the transethnic meta-analysis, we found a 
single locus close to SLC39A8 that was genome-wide 
significant in our meta-analysis of VWF associations in 
European-ancestry samples. This gene, which encodes a 
zinc transporter that functions in the cellular import of 
zinc at the onset of inflammation, has also been associ-
ated with blood pressure, high-density lipoprotein cho-
lesterol levels, and body mass index. Our functional work 
also suggested a strong effect on VWF levels in media 
from endothelial cells in vitro on SLC39A8 silencing.
Although further functional characterization of 
these genes is needed to fully characterize the role of 
all the investigated genes in VWF regulation, our results 
demonstrate that these studies are a valid tool to elu-
cidate functional genes coming from genetic associa-
tions and to shed light into the most relevant biological 
pathways implicated in the regulation of the phenotype 
under study.
MR and Clinical Implications
Our results provide insights into the causal role of FVIII 
and VWF in 3 cardiovascular events, which are the lead-
ing causes of deaths globally.
Biological and genetic evidence indicates that cir-
culating FVIII levels are determined mainly by levels 
of VWF.34 In the present study, we calculated the ge-
netic correlation between VWF and FVIII on the basis 
of the genome-wide association results from European-
descent individuals (Methods in the online-only Data 
Supplement) and found that the proportion of shared 
heritability of between these 2 phenotypes is 83.5%. 
This result is strengthened by the overlapping findings 
found in the individual GWASs and suggests that, with 
some exceptions, the genetic pathways that regulate 
VWF levels indirectly regulate FVIII levels. Given the role 
of VWF regulating FVIII, we used 3 loci that were u-
niquely associated with FVIII independently of VWF and 
pursued conditional analyses that adjusted for the ef-
fect of VWF plasma levels to test the causal effect of 
FVIII on cardiovascular events. For IS, we found no evi-
dence of a causal effect of FVIII that was independent 
of the VWF effect, which suggests that VWF biology 
may causally contribute to IS risk. For VTE and CAD, 
however, we found evidence supporting a causal effect 
of FVIII independently of the VWF effect. Because no 
genetic loci were independently associated with VWF 
levels but not FVIII levels, we could not adjust the VWF 
analyses for FVIII. Nonetheless, given the similarities in 
the magnitude of the VWF-adjusted FVIII causal ORs 
with the VWF causal ORs for VTE and CAD, our data 
suggest that the VWF causal association for VTE and 
CAD may be driven primarily by the biological effect of 
FVIII, although this hypothesis could not be tested.
The results of the MR analyses suggest that both FVIII 
and VWF may be reasonable targets for the prevention 
or intervention of CAD and VTE, whereas VWF may be 
a reasonable target for IS. Indeed, over the past decade, 
this line of thinking and research has been pursued, 
and these molecules are currently under investigation 
as pharmaceutical targets for the prevention of throm-
botic events.35–38 Here, we report 23 unique genetic loci 
associated with plasma levels of FVIII or VWF, of which 
13 are newly reported associations. These discoveries 
may offer new targets in the development of pharma-
ceutical agonistics or antagonists that may modulate 
thrombotic risk.
Strengths and Limitations
A major strength of the study was the relatively large 
sample size and the use of a denser imputation panel 
than was used in past discovery efforts. With this ap-
proach, we had hoped to identify uncommon asso-
ciated variants, but the MAFs of the variants in the 
newly associated loci were relatively common, with 
just 1 variant having an MAF of <0.10. Our study de-
sign did not identify new associations marked by rare 
variation. Increasing the number of study participants 
to increase statistical power or improving the quality 
of the imputation from genotyping arrays may help 
to identify uncommon or rare variants associated 
with the outcomes. Some of the novel findings may 
be false-positives because we did not have access to 
independent populations to replicate our discoveries. 
Replication is required to validate genetic associations, 
especially for those close to the threshold for statisti-
cal significance. To offset this limitation, we conduct-
ed functional validation by silencing candidate genes 
and measuring VWF release; we view this functional 
work as a strength of the study. We were able to test 
only the regulation of VWF expression, not the regu-
lation of VWF clearance by macrophages.39 Nor were 
we able to test other mechanisms that regulate syn-
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thesis in megakaryocytes but not endothelial cells. 
Furthermore, the need for a particular cellular stimu-
lus that cannot be mimicked by histamine stimulation 
for the effect to be produced would be missed by our 
approach. Finally, it could be that the effect of some 
genetic associations can be seen only through over-
expression rather than silencing of the gene. We at-
tempted to also measure FVIII release, but levels were 
too low, so new models are required to validate the 
impact of the candidate genes on FVIII levels; this is 
a limitation of our approach. All functional work was 
done in vitro, which carries limitations relative to in 
vivo investigations. The strong genetic coregulation of 
both FVIII and VWF levels allowed us to conduct mul-
tiphenotype analyses and to increase statistical power 
for discovery. Our MR approach using improved instru-
mental variants allows to establish for the first time a 
causal relationship between VWF and FVIII and several 
cardiovascular events. With only 3 loci associated with 
FVIII alone, the power of the VWF-adjusted MR analy-
ses for FVIII and cardiovascular events was limited, and 
we could not investigate the association of VWF with 
cardiovascular events independently of FVIII. There is a 
degree of overlap between our sample and the sample 
from consortia providing cardiovascular events GWAS 
data, which might create some bias in MR analyses;40 
this is a limitation of our work.
CONCLUSIONS
We found 13 novel genetic loci with modest contribu-
tions to plasma levels of FVIII or VWF. Our discovery 
approach including first-pass functional validation has 
provided relevant information on the best candidate 
gene at the novel loci. Finally, MR analyses provided 
some evidence implicating FVIII plasma levels in the risk 
of CAD and VTE and VWF plasma levels in the risk of IS. 
In summary, our work has identified novel loci regulat-
ing proteins essential for hemostasis and coagulation. 
These findings may provide genetic tools for therapeu-
tic and preventive strategies and may be useful to iden-
tify new biological pathways on which to intervene to 
reduce the burden of arterial and venous outcomes.
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